NEW YORK, July 8 (GenomeWeb News) - Myriad Genetics has won $14.2 million from the National Institute of Allergy and Infectious Diseases to analyze pathogen-host protein interactions using high-throughput proteomics.
Â
Under the five-year contract, Salt Lake City-based Myriad will use its yeast two-hybrid technology, bioinformatics, and DNA sequencing to conduct proteome-wide analyses of protein interactions between humans and selected pathogens. Myriad also plans to validate these interactions by other methods, such as microbial gene knockout and siRNA.
Â
Myriad will have the rights to commercialize diagnostic and therapeutic targets discovered in the project. All protein interaction and validation data will be made publicly available through the Proteomics Research Program Administrative Center.